Impact of Cholecalciferol Treatment on Biomarkers of Inflammation and Myocardial Structure in Hemodialysis Patients Without Hyperparathyroidism

Journal of Renal Nutrition

Volumn 22, Issue 2, 2012, Pages 284-291

  Bucharles, Sérgio ^a,b   Barberato, Silvio Henrique ^a,c   Stinghen, Andréa E M ^a,d   Gruber, Betina ^a   Piekala, Luciana ^b   Dambiski, Ana Cláudia ^b   Custodio, Melani R ^e   Pecoits Filho, Roberto ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^b Instituto do Rim do Paraná   (Brazil)

^c Hospital Cardiologico Costantini   (Brazil)

^d FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^e FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM; COLECALCIFEROL; INTERLEUKIN 6; PARATHYROID HORMONE; PHOSPHORUS; SERUM ALBUMIN; VITAMIN; VITAMIN D;

AGED; ARTICLE; BLOOD; CHEMISTRY; DIET SUPPLEMENTATION; FEMALE; HEART MUSCLE; HUMAN; HYPERPARATHYROIDISM; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; VITAMIN D DEFICIENCY;

AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCIUM; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYPERPARATHYROIDISM; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; MYOCARDIUM; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SERUM ALBUMIN; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84856351047     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.07.001     Document Type: Article

References (44)

1. Foley R.N., Parfrey P.S. Cardiovascular disease and mortality in ESRD. J Nephrol 1998, 11:239-245.
2. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15:2208-2218.
3. Honda H., Qureshi A.R., Heimburger O., et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006, 47:139-148.
4. Del Valle E., Negri A.L., Aguirre C., Fradinger E., Zanchetta J.R. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int 2007, 11:315-321.
5. Gonzalez E.A., Sachdeva A., Oliver D.A., Martin K.J. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004, 24:503-510.
6. Mucsi I., Almasi C., Deak G., et al. Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol 2005, 64:288-294.
7. Dusso A.S., Brown A.J., Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005, 289:F8-F28.
8. Andress D.L. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006, 69:33-43.
9. O'Connell T.D., Berry J.E., Jarvis A.K., Somerman M.J., Simpson R.U. 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997, 272(4 Pt. 2):H1751-H1758.
10. Al-Aly Z. Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients: the need for randomized trials. Kidney Int 2007, 72:909-911.
11. London G.M., Guerin A.P., Verbeke F.H., et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007, 18:613-620.
12. Wang T.J., Pencina M.J., Booth S.L., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
13. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009, 113:S1-S130.
14. Zerwekh J.E. Blood biomarkers of vitamin D status. Am J Clin Nutr 2008, 87:1087S-1091S.
15. Parfrey P.S., Foley R.N., Harnett J.D., Kent G.M., Murray D., Barre P.E. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996, 49:1428-1434.
16. Devereux R.B., Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977, 55:613-618.
17. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986, 57:450-458.
18. Quinones M.A., Otto C.M., Stoddard M., Waggoner A., Zoghbi W.A. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002, 15:167-184.
19. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463.
20. Sohn D.W., Song J.M., Zo J.H., et al. Mitral annulus velocity in the evaluation of left ventricular diastolic function in atrial fibrillation. J Am Soc Echocardiogr 1999, 12:927-931.
21. Pritchett A.M., Jacobsen S.J., Mahoney D.W., Rodeheffer R.J., Bailey K.R., Redfield M.M. Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol 2003, 41:1036-1043.
22. Barberato S.H., Pecoits-Filho R. Prognostic value of left atrial volume index in hemodialysis patients. Arq Bras Cardiol 2007, 88:643-650.
23. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32(5 suppl. 3):S112-S119.
24. Stinghen A.E., Bucharles S., Riella M.C., Pecoits-Filho R. Immune mechanisms involved in cardiovascular complications of chronic kidney disease. Blood Purif 2010, 29:114-120.
25. LaClair R.E., Hellman R.N., Karp S.L., et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005, 45:1026-1033.
26. Lee J.H., O'Keefe J.H., Bell D., Hensrud D.D., Holick M.F. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?. J Am Coll Cardiol 2008, 52:1949-1956.
27. Tokmak F., Quack I., Schieren G., et al. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 2008, 23:4016-4020.
28. Saab G., Young D.O., Gincherman Y., Giles K., Norwood K., Coyne D.W. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007, 105:c132-c138.
29. Jean G., Terrat J.C., Vanel T., et al. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 2008, 23:3670-3676.
30. Panichi V., De Pietro S., Andreini B., et al. Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int 1998, 54:1463-1469.
31. Cohen-Lahav M., Douvdevani A., Chaimovitz C., Shany S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol 2007, 103:558-562.
32. Takahashi K., Horiuchi H., Ohta T., Komoriya K., Ohmori H., Kamimura T. 1 alpha,25-dihydroxyvitamin D3 suppresses interleukin-1beta-induced interleukin-8 production in human whole blood: an involvement of erythrocytes in the inhibition. Immunopharmacol Immunotoxicol 2002, 24:1-15.
33. Pecoits-Filho R., Barany P., Lindholm B., Heimburger O., Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002, 17:1684-1688.
34. Matias P.J., Jorge C., Ferreira C., et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010, 5:905-911.
35. Stubbs J.R., Idiculla A., Slusser J., Menard R., Quarles L.D. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010, 21:353-361.
36. London G.M. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 2002, 17(suppl 1):29-36.
37. Silberberg J.S., Barre P.E., Prichard S.S., Sniderman A.D. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989, 36:286-290.
38. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229-238.
39. Achinger S.G., Ayus J.C. The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int Suppl 2005, 95:S37-S42.
40. Lemmila S., Saha H., Virtanen V., Ala-Houhala I., Pasternack A. Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am J Nephrol 1998, 18:404-410.
41. Park C.W., Oh Y.S., Shin Y.S., et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999, 33:73-81.
42. Coratelli P., Petrarulo F., Buongiorno E., Giannattasio M., Antonelli G., Amerio A. Improvement in left ventricular function during treatment of hemodialysis patients with 25-OHD3. Contrib Nephrol 1984, 41:433-437.
43. Rostand S.G., Drueke T.B. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999, 56:383-392.
44. Holick M.F. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004, 79:362-371.